Summary: Methotrexate (MTX) is a derivative of folic acid (folate) and commonly used as an anchor drug for the treatment of rheumatoid arthritis (RA). The pharmacokinetics (PK) and pharmacodynamics (PD) of MTX entirely depends on the function of specific transporters that belong to the two major superfamilies, solute carrier transporters and ATP-binding cassette transporters. Several transporters have been identified as being able to mediate the transport of MTX, and suggested to be involved in the disposition in the body and in the regulation of intracellular metabolism in target cells, together with several enzymes involved in folate metabolism. Thus, drugdrug interactions through the transporters and their genetic polymorphisms may alter the PK and PD of MTX, resulting in an interpatient variability of efficacy. This review summarizes the PK and PD of MTX, particularly in relation to RA therapy and focuses on the roles of transporters involved in PK and PD with the aim of facilitating an understanding of the molecular basis of the mechanism of MTX action to achieve its effective use in RA therapy.
Introduction
Methotrexate (MTX) is commonly used for the treatment of rheumatoid arthritis (RA). MTX was first introduced as a chemotherapeutic agent to inhibit nucleotide biosynthesis in various cancers such as childhood leukemia and choriocarcinoma. 1) However, a low dose of MTX was later found to be effective for the treatment of RA, and it has now been well recognized as a disease-modifying antirheumatic drug (DMARD).
2) With cumulative evidence of its clinical efficacy in RA therapy and in combination therapy with other DMARDs, MTX has been proven to be safe and tolerable and has thus become the first choice as an anchor drug for most patients with RA.
3) The American College of Rheumatology (ACR) recently published recommendations for DMARDs and biological agents in the treatment of RA. 4) This is a revision update of the 2008 ACR recommendations, which have become the current global standard. The guidelines primarily focus on updates for the use and changes in DMARDs and biological agents, including tumor necrosis factor (TNF) inhibitors and non-TNF biological drugs. One noticeable change from the previous guidelines of 2008 is that a more aggressive treatment for patients during the early phase of RA is recommended. Patients with early RA, defined as a disease duration of <6 months, are categorized based on the definitions of the disease activity with or without poor prognostic features. With the exception of the use of biological agents in patients with high disease activity and poor prognostic features, initiation of treatment is in most cases recommended with one DMARD (hydroxychloroquine, leflunomide, MTX, minocycline, or sulfasalazine) or with a combination of DMARDs, in which MTX may mostly be used as a first-line drug for monotherapy and combination therapy. Hence, it is evident that MTX is becoming an increasingly important drug in the treatment of RA.
MTX is an analogue of folic acid (folate) and, hence, has structural and physicochemical properties considerably similar to those of folate; it has two carboxyl groups in its molecule and both of them are almost completely dissociated in the physiological condition. 5) Because of its hydrophilicity, it is unlikely to cross biological membranes in the body by simple diffusion, suggesting involvement of a carrier-mediated transport system for intestinal absorption, tissue distribution and renal excretion. In accordance with that, several transporters that are able to mediate the transport of MTX have been identified. This review summarizes the pharmacokinetics (PK) and pharmacodynamics (PD) of MTX, particularly in relation to RA therapy and focuses on the roles of transporters involved in PK and PD with the aim of facilitating an understanding of the molecular basis of the mechanism of MTX action in order to achieve its effective use in RA therapy.
Pharmacokinetics of MTX in Patients with RA
In the treatment of RA, MTX is commonly administered orally as a single weekly dose or in a divided weekly dose with an interval of several days. In most cases, treatment is initiated with a dose of 10-15 mg/week, with an increase of 5 mg every 2-4 weeks up to a maximum dose of 20-30 mg/week, depending on the clinical response. Parenteral administration is also recommended in cases of inadequate clinical response or intolerance. 6, 7) Earlier studies have described the PK of MTX in patients with RA. After oral administration, the MTX gets rapidly and efficiently absorbed in the proximal part of the small intestine. Its bioavailability (BA) is relatively high, in the range of 64%-90%. 8, 9) However, considerable variations have been described among individual clinical trials, 10) suggesting an interpatient variability in the PK of MTX. The BA of MTX decreases with an increase in dose in the range of the single oral dose of 25 mg or more, suggesting saturation of the absorption and involvement of the carrier-mediated transport system in the absorption process. 9) After oral administration, its plasma concentration reaches the maximum concentration within 1-2 h and then declines and becomes undetectable at 24 h. In RA patients administered a single oral dose of 10-15-mg MTX, its serum levels are approximately in the range of 0.01-1 µM.
11) The plasma protein binding of MTX is moderate with the fraction bound in the range of 46.5%-54%, 12, 13) and its volume of distribution at steady state is approximately 1 L/kg. 14) MTX can distribute to the synovial fluid, in which the level of MTX is comparable with that in plasma. 15) MTX distributed to tissues and cells is rapidly converted to MTX polyglutamates (MTX-PGs) by the catalytic action of folylpolyglutamate synthase (FPGS), which adds up to six glutamate residues to MTX and enhances its intracellular retention. 16) MTX is primarily excreted in the urine. More than 80% is excreted in the intact form and approximately 3% in 7-hydroxylated form, which is a major metabolite of MTX.
11) Thus, the contribution of renal excretion in elimination is considerably greater than that of hepatic metabolism. MTX is filtered by the glomeruli and also undergoes secretion and reabsorption in the renal tubule. The process of tubular secretion is mediated by specific transporters for organic anions and folates. The contribution of secretion clearance to renal MTX clearance is estimated to be approximately 2.5-fold greater than that of the glomerular filtration rate, indicating the important role of transporters in the secretion of MTX. 17) It is also likely that enterohepatic circulation of MTX occurs because 8.7-26% of doses was found in the bile after intravenous administration of MTX in humans.
18)

Pharmacodynamics of MTX in RA Therapy
The pharmacological action of MTX is primarily attributed to its ability to inhibit multiple enzymes that are involved in de novo biosynthesis of nucleotides, such as dihydrofolate reductase, thymidylate synthase, aminoimidazole carboxamide ribonucleotide transformylase (AICART) and amido phosphoribosyltransferase. Although the mechanism involved in the anti-inflammatory effect of MTX in RA therapy remains controversial, AICART has been proposed as the potential target of MTX in RA.
2) Biochemical studies have shown that MTX-PGs can inhibit the activity of AICART more strongly than MTX, indicating that MTX-PG is the biologically active form of MTX. 19) The inhibition of AICART by MTX-PGs promotes the accumulation of its substrate, AICART ribonucleotide (ZMP), 20) which is a potent inhibitor of adenosine deaminase, and thereby causes an increase in adenosine triphosphate (ATP) and adenosine levels. These intracellular compounds are released into the extracellular space, where activation of signaling pathways by stimulation of adenosine receptors leads to anti-inflammatory action of MTX. 21) More recently, inhibition of the mammalian target of the rapamycin pathway (mTOR) by ZMP has also been proposed as a potential mechanism for the action of MTX in RA therapy. 22, 23) For the prediction of PK/PD of MTX in RA therapy, measurement of the MTX-PGs level in red blood cells (RBC) has been proposed, based on pharmacological and clinical evidence. Several studies have demonstrated that MTX-PGs levels in RBC, but not MTX levels in plasma, 24) are associated with clinical efficacy; therefore, measurements of MTX and MTX-PGs should be able to stand as clinical biomarkers for PK/PD predictions of MTX in RA therapy. 25) However, it should be noted that RBCs lack the ability to synthesize MTX-PGs because of the absence of FPGS; thus, the levels of MTX-PGs measured in RBC presumably represent those synthesized in the bone marrow during erythroblast maturation.
26)
Transporters Involved in the Pharmacokinetics of MTX
The PK of MTX entirely depends on the function of specific transporters that belong to the two major superfamilies, solute carrier (SLC) transporters and ATP-binding cassette (ABC) transporters. 27) Because MTX is a xenobiotic compound with the features of hydrophilicity and organic anionization, mimicking folate as an indispensable nutrient, each process in the PK of MTX such as absorption, distribution, and elimination is mediated not only by multispecific transporters for organic anions but also by those specific for folates. Therefore, it is important to understand the molecular functions of those multiple transporters known to be involved in the PK of MTX.
The role of proton-coupled folate transporter (SLC46A1) and MTX absorption: It has been suggested that intestinal absorption of MTX is mediated by a carrier-mediated transport system specific to folates. 28) Proton-coupled folate transporter (PCFT/ SLC46A1), which is involved in folate absorption, is a member of the SLC family. 29) This transporter was originally identified as a heme transporter and named heme carrier protein 1 (HCP1). 30) However, in 2006, Qiu et al. clearly demonstrated that it functions as a proton-coupled folate transporter. 31) Loss-of-function of the PCFT gene due to genetic mutation leads to hereditary folate malabsorption, indicating that PCFT plays a critical role in the absorption of dietary folate.
The transport activity of PCFT is increased at an acidic pH, with an optimal pH of 5.5, but this activity is negligible at around neutral pH and above. This high pH dependency of PCFT is distinct from that of other proton-coupled transporters, such as peptide transporter 1 (PEPT1/SLC15A1), monocarboxylate transporter 1 (MCT1/SLC16A1), and proton-coupled amino acid transporter 1 (PAT1/SLC36A1), which have modest transport activities even at a near neutral pH. 32) This transport activity significantly decreased when the proton gradient across the plasma membrane was dissi-pated by nigericin, a K + /H + exchanger, indicating that an inwardly directed H + gradient is required to drive this operation. 33) This PCFT is also expected to operate efficiently in vivo because an acidic microclimate environment is known to be physiologically maintained at the luminal surface of the small intestine, in which the pH is suggested to go down to as low as approximately 5.3, depending on the condition.
PCFT recognizes a narrow range of compounds as substrates and can mediate the transport of folates such as oxidized folate, 5-methyl tetrahydrofolate (5-methyl THF), 5-formyl tetrahydrofolate (5-formyl THF), and folate deliveries including MTX and pemetrexed, a new generation of antifolate drug. The values of the Michaelis constant (K m ) of PCFT for folate and MTX are in the micromolar range (1-3 µM for folate and 3-6 µM for MTX) at pH 5.5 and they are comparable with those reported in various intestinal preparations, such as everted sacs and brush-border membrane vesicles. 31, 34) The distribution of PCFT is, however, restricted in the body, being mainly expressed in the proximal part of the small intestine at the apical (brush-border) membrane of enterocytes. The expression of its mRNA is also detected in the liver, kidney, placenta, and choroid plexus, to lesser extents, but not in the distal part of the small intestine or colon in humans. A similar intestinal distribution profile is also observed in rats, and a study using rat everted tissue sacs has shown that the distribution profile of rat PCFT mRNA is in agreement with the transport activities of folate and MTX along the intestinal tract. 33) It is notable that the uptakes of both folate and MTX by simple diffusion are estimated to be negligible in everted tissue sacs and almost undetectable in the lowest ileum, where rat PCFT expression is almost negligible. Based on these, it is most likely that the intestinal absorption of folate and MTX is mostly mediated by PCFT and their diffusive transport is insignificant. Therefore, the luminal concentrations of folate and MTX together with their residence time in the proximal region of the small intestine may be important factors in achieving their complete absorption.
This regional expression of PCFT is regulated at the transcriptional level. In tumor cell lines, DNA methylation in a CpG island of ¹200 to +100 relative to the transcriptional start site is involved in the regulation of PCFT mRNA expression. 35) However, the CpGrich region in the genomic DNA extracted from the rat intestine is not methylated either in the jejunum or the ileum, suggesting the involvement of some other regulation mechanisms in the proximal region of the small intestine. A recent study has shown that the PCFT promoter region is transactivated by KLF4, which is known as a gut-enriched Krüppel-like factor and is highly expressed in terminally differentiated intestinal epithelial cells. 36) Because KLF4 is involved in the intestine-specific expression of various proteins, such as intestinal alkaline phosphatase and sodium-dependent multivitamin transporter, this transcription factor may be involved in the unique expression profile of PCFT in the small intestine. It is also notable that the same study indicated the possible involvement of additional transcription factors, which include hepatocyte nuclear factor 4¡ (HNF4¡), caudal-type homeobox transcription factor 2 (CDX2), and CCAAT/enhancer-binding protein ¡ (C/EBP¡). In the ex vivo culture of rat duodenum biopsies, Eloranta et al. demonstrated that 1,25-dihydroxyvitamin D 3 (vitamin D 3 ) can transactivate the PCFT promoter via a heterodimer complex of vitamin D receptor (VDR) and retinoid X receptor-¡ (RXR¡) and, consequently, increase the mRNA expression and transport function of PCFT.
37) The finding suggests potential drug-drug interaction (DDI) between vitamin D 3 and MTX, in which the intestinal absorption (or bioavailability) of MTX may be enhanced by the intake of vitamin D 3 . Patients suffering from inflammatory bowel disease are frequently on long-term treatment with calcium and vitamin D 3 as a prophylaxis against osteopenia and osteoporosis; therefore, this DDI based on the transcriptional regulation could be clinically relevant. The expression of PCFT mRNA was found to be significantly decreased in the duodenum of patients treated with proton-pump inhibitors (PPIs), such as omeprazole, pantoprazole, and lansoprazole. 38) PPIs per se may also pharmacologically inhibit gastric K + /H + -ATPase and thereby decrease the secretion of protons that could be used to drive PCFT in the duodenum. Therefore, concomitant administration of PPIs may reduce the absorption of folates and MTX.
Direct inhibition of the PCFT function by concomitant drugs may explain the interpatient variability in the PK of MTX. Sulfasalazine, which is a second-line DMARD, inhibits the transport of PCFT with the inhibition constant (K i ) of 42.3-60 µM. 34, 38) Because sulfasalazine is orally administered at a dose of more than 500 mg, its luminal levels in the small intestine would be more than 5 mM, which greatly exceeds the K i . It is possible that this DDI would decrease the efficacy of MTX. Therefore, the use of a combination therapy of MTX and sulfasalazine cannot additively improve the pharmacological efficacy of MTX or sulfasalazine alone.
Pyrimethamine was also found to be an inhibitor of PCFT with the K i of 161.7 µM. 38) Pyrimethamine, an inhibitor of malarial dihidrofolate reductase, is typically used with sulfadoxine for the treatment of toxoplasmosis and given as a single oral dose of 50-75 mg. It is similar to sulfasalazine in that its estimated intestinal levels much exceed the K i , being in the range of 0.67-1 mM, and, hence, it would potentially inhibit the function of PCFT. On the basis of the mechanism of these DDIs, the simultaneous use of a PCFT inhibitor should be avoided in RA therapy with oral MTX to prevent the possible interference of MTX absorption.
The role of reduced folate carrier 1 (SLC19A1) and MTX distribution: Reduced folate carrier 1 (RFC1/SLC19A1) is the first cloned transporter found to transport folates. 39) The functional features of RFC1 are different from those of PCFT, in terms of the mode of operation and substrate specificity. RFC1 is involved in the transport of reduced folates such as 5-methyl THF, a dominant form of folate that is present in the systemic circulation and enters from blood into the cells of peripheral tissues. RFC1 has the ability to transport folate derivatives such as 5-methyl THF, 5-formyl THF, and MTX with high affinities (K m : 1-3 µM for reduced folates and 5-10 µM for MTX). However, its affinity for folate (oxidized form) is considerably lower than that for reduced folates with a K m in the range from 200 to 400 µM, indicating its minor role in the transport of the oxidized form of folate under physiological conditions. It has been reported that the homozygous deletion of mouse RFC1 causes an absence of erythropoiesis in the bone marrow, spleen, and liver along with lymphoid depletion, suggesting its major role in the distribution of reduced folates to hematopoietic organs. 40) RFC1 operates more efficiently at a near neutral pH than at an acidic pH for transporting reduced folates and MTX. This transport is considered to be mediated by an electroneutral anion exchange mechanism, in which reduced folates and MTX are antiported with intracellular OH ¹ or organic phosphates, including thiamin pyrophosphate, which has been identified as a substrate of RFC1. 41) More recently, Zhao and Goldman proposed the interrelationship between the intracellular metabolism of thiamin and influx transport of folates, suggesting the possibility that the intracellular status of thiamine may alter the transport of folates and MTX. 42) RFC1 is ubiquitously expressed in the body. In humans, RFC1 mRNA is highly expressed in the placenta, liver, peripheral blood leucocytes, and central nervous system and, to a lesser extent, in the heart and skeletal muscle. 43) This transporter is also abundantly expressed in the brush border membrane of intestinal epithelial cells in the small intestine of rodents. 44) However, the contribution of RFC1 to the intestinal absorption of folates and MTX is not clear. A study using rat intestinal tissues demonstrated that transport of folate and MTX is undetectable in the lowest ileum and also that PCFT mRNA is almost undetectable in that region, accordingly suggesting that PCFT is required for the uptake of folate and MTX. 33) In contrast, RFC1 mRNA is highly expressed at a level easily detectable by Northern blotting in that region. On the other hand, however, a high dose of 5-formyl THF, which is a preferred substrate of RFC1, is effective in improving the folate status in subjects with a loss-of-function mutation of PCFT, 45) suggesting the possible role of RFC1. Therefore, RFC1 may also play some physiological and pharmacological roles, which remain to be elucidated, in the intestine.
A recent study reported the expression of RFC1 in the synovial tissue of patients with RA. 46) This expression was significantly higher in patients treated with MTX than in those untreated. Considering its clinical use in the treatment for RA, the delivery or entry process of MTX to target cells such as lymphocytes and macrophages in the rheumatoid synovial tissues is of substantial interest, and it is likely that RFC1 plays a major role in that.
Early studies identified a common single nucleotide polymorphism (SNP) of 80G>A (rs1051266) in RFC1, which involves a substitution of His for Arg at residue 27 in the amino acid sequence, without a significant alteration in the transport function of MTX and 5-methy THF. 47, 48) However, several pharmacogenomic studies have shown the possible contribution of 80G>A RFC1 SNP in the PK/PD of MTX. It has been reported that patients with an 80A/A genotype have higher MTX plasma levels than those with a 80G/G or 80G/A genotype in the treatment of childhood acute lymophoblastic leukemia using a high dose of MTX. 49) In a clinical study of RA therapy using a low dose of MTX, Dervieux et al. found that patients with a 80A/A genotype had levels of MTX-PG S in RBCs that were 3.4-fold higher than those with a 80G/G or 80G/A genotype. 50) A recent study also reported that the 80G>A genotype is associated with a low detectability of the longest form of MTX-PGs. 51) Drozdzik et al. reported that patients with the 80A/A genotype had a 3.32-fold higher probability in achieving remission of RA symptoms. 52) In addition, several studies have found the association between RFC 80A/A and the efficacy of MTX in RA. [53] [54] [55] However, conflicting results have been reported in other clinical studies, 56, 57) and the role of RFC1 polymorphisms in MTX responses requires further study.
Folate receptor ¢ in synovial tissue of patients with RA: Folate receptor-¡ (FR-¡/FOLR1) and folate receptor-¢ (FR-¢/FOLR1) are glycosyl phosphatidyl inositol-anchored glycoproteins, which can bind to folates with a high affinity and mediate their transport by endocytosis.
58) FR-¡ is expressed on the apical membrane of polarized cells in the epithelial tissues in the kidney, lung, and choroid plexus, and it is also expressed in a variety of tumors. In contrast, FR-¢ shows a restricted distribution pattern in normal human tissues, and it is mostly expressed in the hematopoietic cells of myelomonocyte lineages. 59) It has been shown that FR-¢ is selectively expressed on activated monocytes and synovial macrophages in the synovial tissue of patients with RA and that the uptake of MTX occurs through receptor-mediated endocytosis in the isolated synovial mononuclear cells. 60) This specific expression has been confirmed by an immunohistochemical study using synovial biopsy samples from patients with RA. 61) A recent study has shown that macrophages expressing FR-¢ are also present in the synovial tissue of patients with osteoarthritis 62) ; therefore, FR-¢ is considered to be a selective cellular marker for activated macrophages in inflamed regions of joints.
FR-¡ and FR-¢ have very high affinities for folate (oxidized form) and 5-methyl THF (K d : 1 nM and 1-10 nM, respectively), but not for MTX (K d : approximately 300 nM). 61) Although the affinities of both FRs for MTX are comparable with those of RFC1 and PCFT, it is unlikely that FRs are involved in the distribution of MTX in the synovial tissue of patients with RA, because a high affinity substrate of 5-methyl THF is present at a high level (5-50 nM) in the plasma. Therefore, the utilization of specific FR-¢-targeted drugs, including an antibody against FR-¢, has been suggested for the diagnosis and therapy of inflammation in patients with RA.
63)
The role of organic anion transporter 3 (SLC22A8) in renal excretion of MTX: Organic anion transporter 3 (OAT3/ SLC22A8) is involved in the renal excretion of various organic anions, and it is predominantly expressed in the basolateral membrane of the renal proximal tubules. 64) Human OAT3 can mediate the transport of MTX with a K m of approximately 17-21 µM. 65, 66) Several studies exploring the relationship between polymorphisms of OAT3 and its transporter functions have been conducted, 67, 68) but there have been no reports showing its association with the PK of MTX, probably because of the very low frequency of functional polymorphisms of OAT3 in humans. In contrast, the contribution of OAT3 in the disposition of MTX has been well characterized in animal models. Using rat renal slices to evaluate the basolateral uptake in renal tubular epithelial cells, the involvement of Oat3 and RFC1 in the basolateral uptake of MTX has been elucidated. 69) In a PK study using Oat3 knockout mice, the renal clearance of MTX was reportedly reduced in Oat3 knockout mice compared with the wild-type mice. 70) This result may serve as supporting evidence that MTX is dominantly excreted via tubular secretion where OAT3 is involved.
OAT3 is known to be extensively inhibited by several types of nonsteroidal anti-inflammatory drugs, which are often prescribed with MTX to reduce the inflammation associated with RA 71, 72) and, hence, have been suggested to alter the PK of MTX. It has been previously reported that coadministration of multiple NSAIDs causes an increase in the elimination half-life of MTX in children with chronic arthritis. 73) However, no significant effect of the concomitant use of NSAIDs, such as naproxen, 74) celecoxibe, 75) or etoricoxib, 76) on the PK of MTX has been reported in adult patients with RA.
The role of ABC transporters in PK of MTX: ABCB1 is a member of the ABC superfamily and known as P-glycoprotein (P-gp). 77) This transporter is well known to be involved in the multidrug resistance of cancer cells and the disposition of a diverse array of drugs in the body. Although there have been several studies on MTX transport by ABCB1, it remains controversial whether MTX is its substrate or not. On the other hand, numerous studies on pharmacogenomics have demonstrated the association between ABCB1 polymorphism and the effectiveness of MTX in RA therapy. 3435C>T (rs1045642), a synonymous SNP of ABCB1 that occurs with higher frequency, has been shown to be associated with the response, probability of symptom remission and incidence of adverse events in the therapy with MTX in patients with RA 78) or juvenile idiopathic arthritis, which is one of the most common chronic rheumatic diseases in childhood, 79) although conflicting observations have also been reported. 80) Since 3435C>T is a silent mutation without apparent functional change of ABCB1 protein, the mechanism of the modulation of the effect of MTX in vivo remains unclear. The possibility that 3435C>T may be linked to transcriptional and posttranscriptional gene regulation has been suggested. 81) ABCC3 is a member of the multidrug resistance-associated protein (MRP) family and known as MRP3. This transporter is located in the basolateral membrane of the hepatocyte and enterocytes, where it is involved in the efflux of intracellular organic anions into blood. 82) ABCC3 can mediate the efflux of MTX with a K m of 0.62 mM 83) and its overexpression results in high resistance to MTX in short-term exposure. 84) Interestingly, ABCC3 can also transport physiological folates such as 5-formyl-THF very efficiently. Thus, it is likely to be involved in folate metabolism. In an animal study using Abcc3 KO mice, Kitamura et al. demonstrated that plasma MTX levels after oral administration were significantly lower in Abcc3 KO mice than in wild-type mice and, accordingly, its hepatic and biliary clearance were significantly greater in the former. 85) They also found that the mucosal-to-serosal transport of MTX in the everted sacs prepared from the duodenum was significantly lower in the KO mice, where a decrease in the intrinsic serosal efflux clearance of MTX was responsible for that. It suggested the involvement of Abcc3 in MTX absorption in the duodenum by mediating its basolateral efflux. Thus, ABCC3 may play a role in the intestinal absorption of MTX and folates.
A more recent pharmacogenomic study showed that a SNP of ¹211C>T ABCC3 (rs4793665), which is located in the promoter region of ABCC3 gene and reported to reduce the expression of its mRNA, is associated with weaker response to MTX in patients with juvenile idiopathic arthritis, 79) suggesting that lower expression of ABCC3 could alter the PK/PD of MTX. It is also possible to assume a potential role of ABCC3 in the regulation of intracellular levels of MTX in the target cells.
Although several other members of the ABC transporter family have also been proven to be able to transport MTX in an ATPdependent manner with a K m in the millimolar range (2.15 mM for ABCC1/MRP1, 79) 2.5-3 mM for ABCC2/MRP2, 86) 0.22 mM for ABCC4/MRP4, 87, 88) 1.3 mM for ABCC5/MRP5, 89) and 0.681 mM for ABCG2/BCRP 90) ), no association of their polymorphisms with the PK/PD of MTX was observed, with the only exception that MRP2 was associated with side effects in a clinical assessment in RA patients treated with MTX.
91)
Intracellular transport system for MTX-PGs: Since intracellular MTX-PGs play an important role in the pharmacological effects of MTX, it is conceivable that factors that regulate intracellular levels of MTX-PGs would be also involved in the PK/PD of MTX in RA therapy. Gamma-glutamyl hydrolase (GGH), which is responsible for the hydrolysis of the glutamyl chain of their polyglutamates, is a key enzyme in the metabolism of folates and MTX. 92) A previous study indicated that 452C>T (rs11545078), a nonsynonymous SNP of GGH, is associated with higher accumulation of long-chain MTX-PG in leukemia cells of patients treated with a high dose of MTX. 93) Missense mutation of GGH (T127I) by 452C>T causes a decrease of the catalytic activity by 67%, compared to that of wild-type, and it is predicted to alter binding affinity for long-chain forms of MTX-PGs, but not for short-chain forms. Thus, the decrease of GGH activity may lead to the accumulation of long-chain MTX-PGs. However, such an association was not found in RA patients treated with a low dose of MTX. 56, 94) On the other hand, ¹401C>T (rs3758149), which is a SNP found in the promoter region of GGH and increases GGH activity by causing the loss of the binding site for an inhibitory transcription factor, 95) is shown to be associated with lower MTXPGs levels in RBC in RA patients treated with a low dose of MTX. 50) Therefore, it is suggested that higher expression of GGH may alter the intracellular levels of MTX-PGs by catalyzing its decomposition. However, GGH is a lysosomal enzyme 96) and its heterologous expression does not alter intracellular levels of polyglutamyl forms of folates or MTX, 97) suggesting the existence of transport systems that can mediate the influx of polyglutamyl forms of folates and MTX across the lysosomal membrane. An early study demonstrated that a facilitative transport system, which can recognize compounds with C-terminal £-glutamate as substrates, 98) is involved in the accumulation of MTX-PGs in lysosomes. This transport system is also likely to be involved in the development of MTX resistance in cancer cells by decreasing the intracellular MTX-PGs levels. 99) However, this molecular identity remains unknown.
Conclusions and Future Direction
In this review, we summarized recent studies on the transporters involved in the PK/PD of MTX in RA therapy. Because the disposition of MTX is entirely regulated by these transporters as summarized in Figure 1 , information about them is indispensable for better understanding of PK/PD of MTX, and could help us understand the interpatient variability in the efficacy of MTX in RA therapy. However, there still remain questions to be clarified, which include what types of cells are targets of MTX action and how intracellular metabolism and disposition of MTX are regulated. Some other transporters, which have not been identified yet, may play a role in the regulation of the intracellular MTX level, together with several enzymes. 100) More studies are needed to further elucidate the molecular mechanism by means of pharmacogenomic and biological approaches. The modulation of PK/PD based on the molecular mechanism is promising for the improvement of the efficacy of MTX, and establish personalized and optimized therapy using MTX for RA patients.
